Health

Positive outlook for first malaria vaccine

Results from clinical trials released yesterday show that a new malaria vaccine has been able to reduce malaria by 58 percent in 6,000 infected sub-Saharan African children aged five to 17 months. These results are the newest development in the effort toward the world’s first effective vaccine against malaria. The trials are the result of a partnership between the global health nonprofit PATH Malaria Vaccine Initiative and GlaxoSmithKline Biologicals, with funding provided by the Bill & Melinda Gates Foundation.

Malaria kills hundreds of thousands of people a year globally, and as Bill Gates reminded us in his 2009 TEDtalk, it is our responsibility to recognize the importance of these deadly problems and to provide continued support toward finding effective solutions.